SCHEMBL4229254

SCHEMBL4229254

CS(=O)(=O)Nc1ccc(-c2ccc(C(=O)O)c(Nc3ccc(F)cc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.48
KIF11 P52732 2/20 0.46
XDH P47989 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
NR3C2 P08235 1/20 0.45
MCL1 Q07820 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
CSF1R P07333 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4221471 0.90 ACLY (0.54) ACLYMCL1AKR1C3AKR1C2CSF1R
SCHEMBL4226484 0.88 XDH (0.54) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4218122 0.88 CSF1R (0.53) ACLYXDHSLC22A12MCL1PTGS2
SCHEMBL4219763 0.84 MEN1 (0.47) NR3C2PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL4223054 0.84 AKR1C3 (0.59) ACLYXDHSLC22A12MCL1AKR1C3
SCHEMBL4215664 0.84 ACLY (0.52) ACLYXDHSLC22A12PTGS1AKR1C3
SCHEMBL4216089 0.83 XDH (0.53) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4209141 0.82 SOS1 (0.54) ACLYXDHSLC22A12PTGS1PTGS2
SCHEMBL4218272 0.82 AKR1C3 (0.61) ACLYXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4224024 0.82 MPO (0.52) XDHSLC22A12AKR1C3AKR1C2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 ACLY 430/4885KIF11 1197/4885XDH 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.